N Jewel Samadder Selected Research

Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)

5/2022	Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
4/2022	Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial.
10/2020	Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
7/2018	Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
1/2018	Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
1/2018	Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
10/2017	Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management.
8/2017	Outcomes and complications of radiation therapy in patients with familial adenomatous polyposis.
8/2016	Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
8/2016	Sulindac and Erlotinib for Familial Adenomatous Polyposis--Reply.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

N Jewel Samadder Research Topics

Disease

12	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 05/2022 - 03/2015
11	Neoplasms (Cancer) 05/2022 - 04/2014
10	Polyps 05/2022 - 04/2014
6	Colorectal Neoplasms (Colorectal Cancer) 12/2019 - 04/2011
4	Adenoma (Adenomas) 04/2022 - 04/2014
3	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2021 - 03/2015
2	Disease Progression 04/2022 - 10/2020
2	Colonic Neoplasms (Colon Cancer) 02/2016 - 12/2012
1	Duodenal Neoplasms (Duodenal Cancer) 07/2018
1	Acne Vulgaris 03/2016
1	Exanthema (Rash) 03/2016
1	Rectal Neoplasms (Rectal Cancer) 02/2016
1	Diverticular Diseases 09/2014
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 04/2011

Drug/Important Bio-Agent (IBA)

8	Sulindac (Copal)FDA LinkGeneric 05/2022 - 03/2016
7	Calcibiotic Root Canal SealerIBA 12/2019 - 04/2014
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 05/2022 - 03/2016
3	Pharmaceutical PreparationsIBA 04/2022 - 01/2018
3	Eflornithine (Ornidyl)FDA Link 04/2022 - 08/2016
2	Biological ProductsIBA 01/2018 - 04/2014
2	SaltsIBA 01/2018 - 03/2016
1	Naproxen (Naprosyn)FDA LinkGeneric 01/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	Drug CombinationsIBA 01/2018
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	Dinoprostone (PGE2)FDA Link 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Interleukin-12 (IL 12)IBA 01/2018
1	PolyaminesIBA 08/2016
1	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 08/2016
1	MucinsIBA 03/2016
1	ORALIT (ORS)IBA 02/2016
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 04/2011
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 04/2011

Therapy/Procedure

5	Colectomy 04/2022 - 08/2016
4	Chemoprevention 01/2021 - 03/2016
3	Therapeutics 04/2022 - 08/2016
2	Restorative Proctocolectomy 04/2022 - 01/2018
1	Endoscopes 12/2019
1	Radiotherapy 08/2017
1	Stents 12/2012